Table 4 Risk assessments of clinical parameters for advanced fibrosis
CharacteristicNAFLD and fibrosis 0–2 n (%)Fibrosis 3–4 n (%)p ValueOR (95% CI)
Age ⩾50 years278 (45)133 (69)<0.0012.7 (1.9 to 3.8)
    Subset 1147 (45)67 (70)<0.0012.8 (1.7 to 4.6)
    Subset 2131 (44)66 (67)<0.0012.6 (1.6 to 4.2)
Female gender298 (48)123 (63)<0.0011.9 (1.3 to 2.6)
    Subset 1160 (49)58 (60)0.0421.6 (1.0 to 2.6)
    Subset 2138 (47)65 (66)0.0012.2 (1.4 to 3.6)
Body mass index ⩾28 kg/m2385 (85)134 (93)0.012.4 (1.2 to 4.8)
    Subset 1206 (86)68 (94)0.052.7 (0.9 to 7.9)
    Subset 2180 (83)67 (92)0.062.3 (0.9 to 5.6)
HTN291 (58)100 (69)0.0101.7 (1.1 to 2.5)
    Subset 1139 (53)44 (64)0.1101.5 (0.9 to 2.7)
    Subset 2152 (62)56 (75)0.041.8 (1.0 to 3.2)
Diabetes153 (27)106 (60%)<0.0014.0 (2.8 to 5.7)
    Subset 173 (24)52 (60)<0.0014.7 (2.8 to 7.8)
    Subset 280 (30)54 (59)<0.0013.4 (2.0 to 5.5)
QUICKI <0.29489 (30)24 (53)0.0022.7 (1.4 to 5.0)
    Subset 149 (29)15 (60)0.0023.6 (1.5 to 8.6)
    Subset 240 (31)11 (55)0.1981.9 (0.7 to 4.8)
QUICKI<0.35267 (90%)45 (100%)0.02*
    Subset 1150 (89%)25 (100%)0.09
    Subset 2117 (90%)20 (100%)0.12
HbA1c ⩾6.0%148 (43)67 (58)0.0051.8 (1.2 to 2.7)
    Subset 169 (41)35 (58)0.0102.0 (1.1 to 3.7)
    Subset 279 (45)32 (57)0.1201.6 (0.9 to 2.9)
Hyperlipidaemia253 (45)55 (36)0.0100.6 (0.4 to.9)
    Subset 1131 (44)26 (31)0.0400.6 (0.3 to.9)
    Subset 2122 (46)29 (36)0.1100.7 (0.4 to 1.1)
AST/ALT ⩾0.8153 (26)141 (76)<0.0019.3 (6.3 to 13.6)
    Subset 184 (27)72 (79)<0.00110.4 (5.9 to 18.3)
    Subset 269 (25)69 (73)<0.0018.4 (5.0 to 14.4)
  • *OR for QUICKI <0.350, not calculable.

  • ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; HTN, hypertension; OR, odds ratio; QUICKI, quantitative assessment check index.